Aldo-keto reductase 1C3 (AKR1C3) is a monomeric enzyme expressed in steroidogenic tissues such as the testis, prostate, uterus, and breast. Overexpression of this AKR1C3 is associated with vast cancers such as breast, colon, colorectal, endometrial, prostate, and acute myeloid leukaemia. Regarding the treatment of castration-resistant prostate cancer, breast cancer, and acute myeloid leukaemia, AKR1C3 inhibitors may offer clear advantages over currently available therapies. Thus, discovering novel and specific AKR1C3 inhibitors is a promising way to obstruct drug resistance in cancer. Derivatives of alpha-tocopherol and alpha-tocopheroids were selected as possible therapeutics to act as AKR1C3 inhibitors. The precise targets of several ligands were determined using computational screening methods. The molecular structure of AKR1C3 and its ligands were used as the foundation for in silico predictions, modelling, and dynamic simulations. Compounds were selected based on their biological properties and filtered according to their ADMET and drug-likeness properties. Additionally, simulations of all-atom molecular dynamics on AKR1C3 with the cleared compounds revealed stability over the simulated trajectories of 100 ns. When seen collectively, alpha-tocospiro A may be considered prospective AKR1C3 inhibitors for creating anticancer therapies.Communicated by Ramaswamy H. Sarma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07391102.2023.2241543 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exosomal miR-184 facilitates bladder cancer progression by targeting AKR1C3 and inducing immune escape via IRF2-CXCL10 axis.
Biochim Biophys Acta Mol Basis Dis
December 2024
Department of Urology, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address:
Currently, the molecular mechanisms underlying bladder cancer progression remain unclear. Immune checkpoint inhibitors (ICIs) have been used to treat bladder cancer, but their efficacy is limited. Exosomes, which play a critical role in cell communication, can alter the tumor microenvironment.
View Article and Find Full Text PDFThe third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.
Blood Cancer J
November 2024
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1 member C3 (AKR1C3). To exploit this finding, we developed a novel prodrug, ACHM-025, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent. We show that ACHM-025 has potent in vivo efficacy against T-ALL patient-derived xenografts (PDXs) and eradicated the disease in 7 PDXs.
View Article and Find Full Text PDFAldo-Keto reductase 1C3 reduces myocardial cell damage after acute myocardial infarction by activating the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-antioxidant response element pathway to inhibit ferroptosis.
J Geriatr Cardiol
September 2024
Department of Cardiology, Shunde Hospital, Southern Medical University, the First People's Hospital of Shunde, Foshan, China.
Background: Acute myocardial infarction (AMI) is a high-risk cardiovascular condition associated with increased cellular damage and oxidative stress. Aldo-Keto Reductase 1C3 (AKR1C3) is a stress-regulating gene. Nevertheless, its specific role and mechanisms regarding AMI remain unclear.
View Article and Find Full Text PDFSynthesis and biological evaluation of novel D-ring fused steroidal (2)-substituted-1,2,3-triazoles.
RSC Med Chem
October 2024
Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad Trg Dositeja Obradovića 3 21000 Novi Sad Serbia
In this study, a series of 13 new D-ring fused steroidal (2)-substituted-1,2,3-triazoles were synthesized, characterized and evaluated for their biological activities. The relative binding affinities of the synthesized compounds for the ligand-binding domains of estrogen receptors α and β, androgen receptor and glucocorticoid receptor demonstrated that androstane derivatives 3a and 3h and estratriene derivative 4e showed highly specific and strong binding affinity for estrogen receptor β, while 3b, 3e, 4a and 4b displayed high binding affinity for the glucocorticoid receptor. The synthesized compounds were tested for their ability to inhibit aldo-keto reductases 1C3 and 1C4 by monitoring NADPH consumption using fluorescence spectroscopy.
View Article and Find Full Text PDFAldo-keto reductase family 1 member C3 mediates radioresistance of esophageal cancer cells through suppressing MAPK and AKT signaling.
BMC Cancer
October 2024
Department of Gastroenterological Surgery, Tangshan People's Hospital, Tangshan, Hebei, 063001, China.
Article Synopsis
- AKR1C3 is identified as a gene linked to radioresistance in esophageal cancer, with higher expression in radioresistant tumors compared to radiosensitive ones.
- By silencing AKR1C3 in esophageal cancer cells, researchers observed increased radiosensitivity and reactive oxygen species (ROS) production, suggesting a role in how these cells respond to radiation.
- The study indicates that AKR1C3 may influence radioresistance through specific signaling pathways, including MAPK and AKT, as inhibiting these pathways affected cancer cell responses to radiation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!